Intrathecal morphine plus general anesthesia in cardiac surgery: effects on pulmonary function, postoperative analgesia, and plasma morphine concentration.

OBJECTIVES: To evaluate the effects of intrathecal morphine on pulmonary function, analgesia, and morphine plasma concentrations after cardiac surgery.
INTRODUCTION: Lung dysfunction increases morbidity and mortality after cardiac surgery. Regional analgesia may improve pulmonary outcomes by reducing pain, but the occurrence of this benefit remains controversial.
METHODS: Forty-two patients were randomized for general anesthesia (control group n=22) or 400 microg of intrathecal morphine followed by general anesthesia (morphine group n=20). Postoperative analgesia was accomplished with an intravenous, patient-controlled morphine pump. Blood gas measurements, forced vital capacity (FVC), forced expiratory volume (FEV), and FVC/FEV ratio were obtained preoperatively, as well as on the first and second postoperative days. Pain at rest, profound inspiration, amount of coughing, morphine solicitation, consumption, and plasma morphine concentration were evaluated for 36 hours postoperatively. Statistical analyses were performed using the repeated measures ANOVA or Mann-Whiney tests (*p<0.05).
RESULTS: Both groups experienced reduced FVC postoperatively (3.24 L to 1.38 L in control group; 2.72 L to 1.18 L in morphine group), with no significant decreases observed between groups. The two groups also exhibited similar results for FEV1 (p=0.085), FEV1/FVC (p=0.68) and PaO2/FiO2 ratio (p=0.08). The morphine group reported less pain intensity (evaluated using a visual numeric scale), especially when coughing (18 hours postoperatively: control group= 4.73 and morphine group= 1.80, p=0.001). Cumulative morphine consumption was reduced after 18 hours in the morphine group (control group= 20.14 and morphine group= 14.20 mg, p=0.037). The plasma morphine concentration was also reduced in the morphine group 24 hours after surgery (control group= 15.87 ng.mL-1 and morphine group= 4.08 ng.mL-1, p=0.029).
CONCLUSIONS: Intrathecal morphine administration did not significantly alter pulmonary function; however, it improved patient analgesia and reduced morphine consumption and morphine plasma concentration.

INTRODUCTION

Lung dysfunction after cardiac surgery is the most frequently reported cause of postoperative morbidity.1,2 In fact, postoperative atelectasis occurs more frequently in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) than in any other type of surgery3 In patients undergoing cardiac surgery, death caused by respiratory complications has been reported as being more frequent than that due to cardiac causes.4 Adequate perioperative analgesia enables full expansion of the chest, thereby contributing to reduce lung collapse in spontaneously breathing patients. This therapeutic intervention may reduce morbidity, hospital costs, and length of stay, thus improving patient quality of life and reducing the incidence of chronic pain.5

The impact of postoperative regional analgesia on major outcomes in non-cardiac surgery has been studied.6–8 Small doses of opioids administered to the central nervous system provide adequate analgesia, reducing the risks of intravenous analgesic administration, such as respiratory depression, pruritus, nausea, and vomiting. However, in the cardiac surgical population, regional anesthesia techniques are not routinely applied due to the scarcity of supporting studies and administration risks associated with preoperative systemic anticoagulation9 Low doses of intrathecal morphine used to control postoperative pain has been shown to promote prolonged analgesia,5 and has been associated with a lower risk of hematoma formation compared to the epidural technique.10 Intrathecal morphine has been studied for several years in patients undergoing cardiac surgery, but these studies were primarily directed towards evaluation of pain control and hemodynamic stability, and did not consider its possible impact of intrathecal morphine on respiratory function recovery.11

The objective of this study was to evaluate the effects of intrathecal morphine on pulmonary function, postoperative analgesia, and morphine plasma concentrations in patients undergoing coronary artery bypass surgery (CABG) with cardiopulmonary bypass (CPB) in comparison to standard intravenous analgesia.

MATERIALS AND METHODS

After approval of the hospital ethics committee and collection of free informed consent, forty-two patients undergoing CABG with CPB and ranging in age from 18 to 80 years were included. Exclusion criteria were an ejection fraction below 40%, contraindications to neuraxial blockage, coagulopathy, use of low-weight heparin, warfarin, intrathecal morphine, or a platelet aggregation inhibitor other than aspirin, systemic or local infection, combined procedures, and patients with a specific contraindication to the medication employed in this study. Preoperative aspirin use was not an exclusion criterion. Preoperative surgical risk was evaluated using Higgins Surgical Risk Scale for cardiac surgery, and patients were considered: (1) minimum risk, (2) low risk, (3) moderate, (4) high, (5) extreme risk12. The patients were randomly assigned to receive general anesthesia with prior administration of intrathecal morphine at a dosage of 400 μg (morphine group n=20) or general anesthesia alone (control group n=22) according to a simple computer-generated list.

Anesthesia and surgical procedures

On the day of the operation, the patients received 1 to 2 mg kg −1 of midazolam orally 30 minutes before surgery, up to a maximal dose of 15 mg. Patients were monitored by continuous ECG and ST-analysis, pulse oximetry, and an invasive arterial line inserted in the right radial artery. In the morphine group, a 400-μg intrathecal injection of morphine was administered using a 27-gauge spinal needle in the L3-L4 space prior to induction of general anesthesia. If intrathecal puncture was not successful after two attempts, the patient was excluded from the study.

After pre-oxygenation, general anesthesia was induced using 0.3 mg/kg of hypnomidate, 0.1 mg kg−1 of pancuroniun bromide, and 0.5 μg kg−1 of sufentanil first as a bolus, followed by a continuous infusion at 0.5 μg kg−1 h−1. Mechanical ventilation was initiated using a Cícero ventilator (Dräger®, Germany) with a tidal volume of 8 ml kg−1, respiratory frequency of 12 ipm, oxygen inspired fraction of 0.6%, and 5 cm of H2O PEEP. A nasoesophageal thermometer, bladder catheter, and central venous catheter were inserted after anesthesia induction. When judged necessary by the attending anesthesiologist, a pulmonary artery catheter was placed in the right internal jugular vein. Immediately after intubation and after CPB weaning, a lung expansion maneuver using an airway pressure of 30 cmH2O for 20 seconds was performed to revert any intraoperative lung collapse. During CPB, hypnosis was maintained with a propofol infusion aimed at maintaining a calculated plasma propofol concentration of 2.5 ug ml−1 according to the Marsh model13. All patients received 1 g of methylprednisolone intravenously before initiation of CPB according to the institutional protocol. Sufentanil infusion was terminated at the moment of skin suture.

After arrival in the intensive care unit (ICU), a patient-controlled analgesia pump (PCA) programmed for a 1 mg bolus of morphine with an administration interval locked at 5 minutes and free demand was installed. Dipyrone (30 mg kg−1) was administered if patients presented persistent pain despite the use of PCA. Tracheal extubation was performed when patients were fully awake and responsive to verbal commands, as well as when the peripheral oximetry was greater than 94%, spontaneous respiratory frequency was greater than 10, temperature was greater than 36° C, and the patient was hemodynamically stable such that they were bleeding less than 100 ml/h.

Ventilatory and pain score evaluation

Spirometry using an Easy One® portable spirometer (Niche Medical, West Leederville, Australia) was also performed preoperatively in the first and second postoperative days (POD) to measure forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and thus the FEV1/FVC ratio. Arterial blood samples were collected during the preoperative period, immediately before surgery, after anesthesia induction, at the end of surgery, and in the first and second postoperative days to evaluate the PaO2/FiO2 ratio. Pain was evaluated using a visual numeric scale from zero to ten at rest, at the time of profound inspiration, and after cough at 3, 6, 12, 18, 24, and 36 hours postoperatively. Morphine cumulative consumption and solicitation was also evaluated at the same times listed above. All postoperative pain, respiratory function, and morphine utilization measurements were obtained by individuals who were not involved in patient randomization and anesthesia administration.

Blood samples assessed for plasma morphine concentrations were collected intraoperatively, immediately after stopping sufentanil infusion, after 5, 15, 30, and 60 minutes, and after 3, 6, 12, 18, 24, and 36 hours in the ICU. The blood samples were centrifuged at 10.000 rpm for 10 minutes, and the supernatant was frozen at − 70 ºC for later analysis. Plasma morphine concentrations were measured using a mass spectrophotometer.

Sample size and statistical analysis

A sample size of at least 36 patients was deemed necessary to detect a statistically significant decrease (p < 0.05) in cumulative morphine consumption of 20% between the morphine and control group, assuming a standard deviation of 10 mg in a single-tail paired Student’s t-test using G Power 3 software (Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany).

Statistical analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, Ilinois). The normal distribution of the collected data was confirmed by means of the Kolmogorov-Smirnov test. Demographic and surgical data were compared between groups using the unpaired Student’s t-test. Spirometric variables were compared over time between the groups using repeated measures analysis of variance, followed by the Student-Neumann-Keuls post hoc test when necessary. Pain scores and cumulative morphine consumption were analyzed by means of the Friedman test, followed by the Mann-Whitney test when necessary. All data are presented as mean values ± standard deviation, error means, or as otherwise described. The significance level was fixed at 5%.

RESULTS

Patient characteristics and general variables are presented in Table 1. There were no differences between groups with regard to the variables represented in Table 1. Mean surgery duration and CPB length were similar in both groups (392 ± 70 vs. 379 ± 91 minutes) and (98 ± 26 vs. 95 ± 38 minutes) (p=0.606 and p=0.780, respectively). Minimal temperature values were 31.3 ± 2.7°C in the control group and 30.7 ± 2.7°C in the morphine group (p=0.456). All patients achieved hemodynamic stability in the immediate postoperative period, permitting weaning off of the vasoactive drugs within the first 24 hours. The total dose of sufentanil employed was 257.77 μg ± 81.41 in the control group and 200.87 μg ± 55.11 in the morphine group (p= 0.012), and was related to the duration of surgery. Intrathecal morphine did not shorten the postoperative time to extubation between groups (396 ± 234 min in the control group and 349 min ± 175 in the morphine group, p=0.466). None of the patients in our cohort developed respiratory failure after extubation or needed postoperative non-invasive ventilation. All intrathecal punctures were successful at the first or second attempt. No cases of spinal hematoma or treatable pruritus were observed. All patients were discharged from the ICU without postoperative complications.

Table 1 -

Sex, Age, IMC, Higgins Surgical Risk Scale, Extubation time, Surgical time, Extracorporeal duration, Minimal temperature at Extracorporeal Circulation between groups. Total dose of sufentanil. Values represent means ± SD. *Chi-square Test **Independent T-student Test, p < 0.05

	Control	Morphine	p-value
Sex (M: F)	20:02	16:04	0.313*
Age (years)	63.8 ± 11.3	60.9 ± 7.6	0.361**
BMI (Kg/cm2)	27.1 ± 3.1	24.4 ± 3	0.071**
Higgins Surgical Risk Scale (0–5)	1.727 ± 1.08	2±1.21	0.546**
Surgery Duration (min)	392.5 ± 70.30	379,5 ± 91,00	0.606**
Tracheal Extubation Time (min)	396.5 ± 234.20	349.1± 175.10	0.466**
CPB Time (min)	98.27 ± 26.90	95.55 ± 38.26	0.790**
Minimal Temperature at CPB (°C)	31.30 ± 2.70	30.68 ± 2.66	0.456**
Total Dose of Sufentanil (μg)	257.77 ± 81.41	200.87± 55.11	0.012**

Chi-square Test,

Independent T Samples Test

Gas exchange and Spirometric Analysis

Both group presented a significant decrease in FVC and FEV1 during the first and second postoperative days, with no significant difference between the groups (p=0.068 and 0.085, respectively). The FEV1/FVC ratio did not differ between groups (p=0.68), as presented in Table 2. In ratio did not differ between groups addition, the PaO2/FiO2 at any time point (p >0.05), as presented in Figure 1.

Table 2 -

Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), and FEV1/FVC ratio at preoperative, and first and second postoperative days (P.O.D.) *ANOVA, p< 0.05

	Groups	Pre-op	1st º POD	2nd POD	P-value*
FVC	Control Group	3.24±0.85	1.45±0.60	1.38±0.53	0.0679
	Morphine Group	2.72±0. 68	1.18±0,45	1.26±0.42
FEV1	Control Group	2.41±0.73	1.06±0.46	1.02±0.54	0.085
	Morphine Group	1.96±0.64	0.90±0.32	0.95±0.26
FEV1/FVC	Control Group	0.75±0.11	0.77±0.19	0.79±0.35	0.685
	Morphine Group	0.74±0.14	0.77±0.14	0.78±0.15

Figure 1 -

PO2/FIO2 ratio between groups, p= 0.078 (means ± DP). P.O.D. = postoperative day. ANOVA, *p<0.05

Pain scores, morphine consumption, and plasma concentrations

The intensity of pain at rest and with cough was significantly lower in the morphine group at 12, 18, 24, and 36 hours postoperatively when compared to the control group (p <0.05), as shown in panels A and C of Figure 2. With profound inspiration, patients in the morphine group reported pain levels that were significantly less intense at 12, 18, and 24 hours after surgery (panel B of Figure 2). The venous morphine solicitation count was lower in the morphine group at 18 (control group= 108.3 ± 213.8 and morphine group= 20.2 ± 30.3) and 24 hours (control group= 144.4 ± 251.2 and morphine group= 32.4 ± 38.05) (p<0.05). Cumulative morphine consumption was also reduced in the morphine group at 18 (control group= 20.14 ± 17.73 mg and morphine group=14.10 ± 26.15 mg), 24 (control group= 27.82 ± 22.77 mg and morphine group= 13.55 ± 10.49 mg), and 36 hours (control group = 38.50 ± 26.70 and morphine group= 24.30 ± 14.59) postoperatively (Figure 3), as well as upon extubation (control group= 3.32 ± 8.17 mg and morphine group= 0.15 ± 0.49 mg) (p<0.05). Plasma morphine levels were zero at the end of surgery in both groups. However, plasma levels were significantly reduced in the morphine group during the postoperative period 24 hours after the operation (control group= 15.87 ± 18.05 ng mL−1 and morphine group 4.08 ± 5.28 ng mL−1, p=0.029), as presented in Figure 4. Nine patients in the control group and five patients in the morphine group requested rescue analgesia with dipyrone (p= 0.460).

Figure 2 -

Intensity of Pain between groups (means ± SEM). A. Pain at rest (p-value at 12, 18, 24, and 36h was 0.0095; 0.0013; 0.0089; 0.0446, respectively). B. Pain upon profound inspiration (p-values were 0.0291; 0.0005; 0.0004, respectively). C. Pain upon cough (p-values at 12, 18, 24, and 36 hours were 0.0019; 0.0010; 0.0218; 0.0145. - Mann-Whitney Test, p<0.05)

Figure 3 -

Cumulative morphine consumption between groups (means ± SEM). P-values at 18 and 24 hours were 0.0373 and 0.0283, respectively. Mann-Whitney Test, *p<0.05

Figure 4 -

Plasma Morphine Levels between groups, p-value=0.029 at 24 hours. Mann-Whitney, *p<0.05

DISCUSSION

In the present study, intrathecal morphine administration in patients undergoing coronary artery bypass graft reduced pain scores, postoperative morphine solicitation, and morphine consumption and its plasma concentration. However, despite better analgesic control, no significant improvements in spirometry or gas exchange were observed.

Respiratory system dysfunction is the most prevalent organic complication after cardiac surgery, even in the absence of preoperative pulmonary disease1. Perioperative atelectasis leads to a pulmonary ventilation/perfusion mismatch that likely serves as a major cause of shunt and hypoxemia after cardiopulmonary bypass.14 The impact of postoperative analgesia techniques on pulmonary function outcome has been well studied in non-cardiac surgery, but few studies to date have examined this matter in cardiac surgery.8 A study that enrolled 113 patients submitted for different types of cardiac surgery observed that thoracic epidural analgesia (TEA) combined with general anesthesia followed by patient-controlled thoracic epidural analgesia offered no major advantages with respect to lung function, length of hospital stay, quality of recovery, or morbidity when compared to general anesthesia alone, with both groups followed by patient-controlled analgesia with intravenous morphine.15 In contrast, a meta-analysis including 15 trials enrolling 1.178 patients suggested that TEA significantly reduced the risk of pulmonary complications (OR 0.41), time to tracheal extubation by 4.5 hours, and analog pain scores at rest and with activity.9

In the present study, intrathecal instead of epidural morphine was used because there is no evidence for analgesia superiority between them. However, the risk of spinal hematoma is lower with the intrathecal technique,16 especially with the required anticoagulation prior to cardiac surgery.

The last two meta-analyses used to evaluate the use of intrathecal morphine in cardiac surgery did not reveal a correlation between the efficacy of pain control and better respiratory outcome,3,11 likely because these studies did not employ lung function as an end-point11. Some of these studies described no improvement of pain control10 or modest reduction of pain scores,11 with higher doses correlating with better postoperative analgesia17 as well as longer time to extubation.18 In line with the beginning of the fast-track era and its goal to decrease the intubation time after surgery, changes in anesthesia techniques and a reduction in the dose of intrathecal morphine were previously associated with a decreased time to extubation,20 with some cases of prolonged respiratory depression.21 A previous study compared intrathecal morphine doses of 250 and 500 μg and placebo, and showed the superiority of intrathecal analgesia, without alterations in gas exchange19 or an increase in time to extubation.22 In the present study, the selected dose of 400 μg of morphine had no effect on time to tracheal extubation in the postoperative period. According to our results, use of low doses of intrathecal morphine can decrease the intensity of postoperative pain at different times, such as at rest, upon profound inspiration, and upon cough. This suggests that not only does intrathecal morphine provide better analgesia at rest, but also during activities that support walking, respiratory maneuvers, and the use of incentive spirometry. This is important to ensure the quality of patient recovery, since it has been demonstrated that respiratory physiotherapy may reduce rates of pulmonary complications.23–25

Improved analgesia may allow for a decrease in the solicitation and consumption of postoperative analgesics, resulting in lower plasma analgesic levels, as observed in this study. A previous cardiac surgery study that also used intrathecal morphine revealed a venous consumption of 13.5 mg at a dose of 250 μg, and a consumption of 11.7 mg of morphine with an intrathecal dose of 500 μg compared to 21.7 mg in the placebo group 24 hours after the operation.22 In a meta-analysis, 668 patients undergoing cardiac surgery were reported to consume 11 mg of intravenous morphine in intrathecal group .9

The importance of studying the plasma concentration of morphine as a marker for progress in the of treatment of pain was considered by Bonica in 1985, but only a few studies have investigated this idea26 Only one study has been published regarding plasma morphine concentrations during patient control analgesia techniques,27 and no studies reported intrathecal morphine use in the postoperative period or its correlation with pain scores. In patients undergoing hysterectomy with postoperative PCA, an increase in plasma morphine levels resulted in clinical effects 6 to 12 hours after surgery. This lag could be explained by the delay in morphine passing through the hematoencephalic barrier. After this period, a significant reduction in morphine consumption and pain scores was observed, and this can be explained by maintenance of a steady-state level of morphine sufficient to maintain an effective level of analgesia.27 Mutations in the opioid μ receptor were described to support the interindividual variability theory in the population and its possible influences on the use of morphine.28–30

Although the number of patients in our study was insufficient to fully evaluate the adverse effects of intrathecal morphine, no cases of spinal hematoma or treatable pruritus were observed in the present study. Previous studies utilizing doses between 5–24 μg kg−1 for cardiac surgery described a 30% incidence of pruritus,21 which is the most common symptom observed after morphine treatment. Fortunately, this common side effect becomes severe in only 1% of cases.31 The absence of an intrathecal puncture in the control group may have limited our ability to observe adverse effects.

Despite the risk of spinal hematoma, the use of intrathecal analgesia in cardiac surgery32 has increased. This increase may be explained by the demand for better analgesia with chest tubes, sternotomy, deambulation, and physiotherapy maneuvers in the absence of a trained pain management team and patient-control pumps. Thus, our study has direct clinical applications. Future studies are being conducted to study the effects of pain control on quality of life, satisfaction, and postoperative recovery, since no additional benefits of intrathecal morphine beyond pain control have been shown until now. None of these quality of life or recovery variables have been correlated with better pain scores, but a modest reduction in satisfaction was shown in the presence of adverse effects.33 Considering the risks of nerve blockade and required anticoagulation in cardiac surgery, further efforts are required to identify better pain control to ensure better patient outcomes.